Clinical Trials Directory

Trials / Conditions / Recurrent Pancreatic Carcinoma

Recurrent Pancreatic Carcinoma

22 registered clinical trials studyying Recurrent Pancreatic Carcinoma — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingMeasuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04550494
National Cancer Institute (NCI)Phase 2
TerminatedBinimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutat
NCT04390243
Academic and Community Cancer Research UnitedPhase 2
Active Not RecruitingGuadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder C
NCT03257761
University of Southern CaliforniaPhase 1
CompletedPembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
NCT03095781
Emory UniversityPhase 1
CompletedAPN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid
NCT03087591
Wake Forest University Health SciencesPhase 1
CompletedAscorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic
NCT02896907
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityEARLY_Phase 1
Active Not RecruitingHypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Ca
NCT03073785
University of NebraskaPhase 2
Active Not RecruitingFOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreat
NCT02890355
National Cancer Institute (NCI)Phase 2
TerminatedTLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro
NCT02650635
Mayo ClinicPhase 1
CompletedBATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
NCT02620865
Barbara Ann Karmanos Cancer InstitutePhase 1 / Phase 2
CompletedAfatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Can
NCT02451553
University of WashingtonPhase 1
Active Not RecruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph
NCT02465060
National Cancer Institute (NCI)Phase 2
CompletedNeoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Canc
NCT02349867
Virginia Commonwealth UniversityPhase 1
CompletedDinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surg
NCT01783171
National Cancer Institute (NCI)Phase 1
CompletedRomidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun
NCT01638533
National Cancer Institute (NCI)Phase 1
CompletedSelumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Pa
NCT01658943
National Cancer Institute (NCI)Phase 2
Active Not RecruitingGemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer
NCT01660971
National Cancer Institute (NCI)Phase 1
CompletedCarboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pan
NCT01280058
National Cancer Institute (NCI)Phase 2
CompletedVismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
NCT01195415
National Cancer Institute (NCI)Phase 2
CompletedGamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
NCT01131234
National Cancer Institute (NCI)Phase 1
CompletedGemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancrea
NCT01064622
National Cancer Institute (NCI)Phase 2
Active Not RecruitingGDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metas
NCT00878163
National Cancer Institute (NCI)Phase 1